The Food and Drug Administration has approved Zurzuvae, or zuranolone, as the first oral medicine specifically indicated to treat postpartum depression in adults. The August 4 approval establishes a 14-day treatment course of 50 milligrams taken once each evening with a fatty meal, offering a short-duration oral alternative in a condition where the only previously approved disease-specific therapy required intravenous administration in a health-care setting.

The decision follows two randomized placebo-controlled trials in which patients receiving zuranolone showed significantly greater improvement in depressive symptoms at day 15, measured with the 17-item Hamilton Depression Rating Scale. The FDA says benefits remained evident at day 42, four weeks after the final dose, although the label also carries a boxed warning about impaired ability to drive or perform other hazardous activities for at least 12 hours after each dose.

A two-week course produced improvement within days

The FDA’s Drug Trials Snapshot summarizes evidence from two studies involving 345 patients with postpartum depression across 125 sites in the United States, Spain and the United Kingdom. Participants entered the studies with significant depressive symptoms, and the primary endpoint in both trials was change in HAMD-17 score at day 15.

The larger recent phase 3 study, SKYLARK, was published online July 26 in the American Journal of Psychiatry. Among 196 randomized participants, patients receiving 50 milligrams of zuranolone had a 15.6-point mean reduction in HAMD-17 score at day 15 compared with an 11.6-point reduction with placebo, a four-point difference. Improvements were also observed at days 3, 28 and 45.

Biogen and Sage had previously reported the trial’s topline findings in a June 2022 announcement. That study enrolled 200 women and found statistically significant symptom improvement beginning by day 3 and sustained through day 45, with somnolence, dizziness, sedation and headache among the more common treatment-emergent adverse events.

The drug acts through a different pathway from standard antidepressants

Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors, part of the brain’s principal inhibitory signaling system. That mechanism differs from common antidepressants that primarily target serotonin, norepinephrine or related monoamine pathways and often require longer courses before patients experience full benefit.

An earlier randomized JAMA Psychiatry trial tested 30 milligrams of zuranolone in women with postpartum depression. In that study, HAMD-17 scores fell by 17.8 points by day 15 in the treatment group compared with 13.6 points for placebo. Differences were visible by day 3 and persisted through day 45, providing an earlier signal that a short course could produce relatively rapid improvement.

The FDA approval is for postpartum depression, not for major depressive disorder more broadly. Biogen and Sage said in their approval announcement that the agency approved the postpartum indication while issuing a complete response letter for the separate major-depressive-disorder application. That narrower decision keeps the initial commercial use focused on the population for which the evidence was strongest.

Safety and driving impairment will shape real-world use

The boxed warning is unusual enough to be operationally important. Patients are instructed not to drive or operate heavy machinery until at least 12 hours after taking a dose because zuranolone can cause sedation and impair psychomotor performance, and patients may not be able to judge accurately how impaired they are.

Other common adverse effects include dizziness, diarrhea, fatigue, nasopharyngitis and urinary tract infection. The FDA also warns about suicidal thoughts and behavior, as it does with other antidepressant treatments, and says the medicine may cause fetal harm. Patients who can become pregnant are advised to use effective contraception during treatment and for one week after the final dose.

The clinical development program also includes the registered SKYLARK study, a randomized double-blind placebo-controlled phase 3 trial of women with severe postpartum depression. The trial design followed patients beyond the 14-day treatment period to assess whether improvements persisted after dosing stopped.

The approval creates a new treatment window for a serious maternal condition

Postpartum depression can impair sleep, functioning, bonding and the ability to care for both mother and infant, and severe cases can include suicidal thoughts. Standard antidepressants and psychotherapy remain important treatment options, but they may take weeks to produce meaningful improvement, while the previously approved brexanolone treatment requires a continuous intravenous infusion in a certified facility.

A two-week oral course could therefore fit into care differently. Obstetricians, psychiatrists and primary-care clinicians may be able to initiate a targeted treatment without arranging a multiday infusion, while the rapid-onset data may be particularly meaningful when symptoms are severe and the consequences of delayed improvement are substantial.

The approval does not answer every practical question. Cost, insurance coverage, controlled-substance scheduling and distribution will influence how widely Zurzuvae is used. Clinicians will also need to decide which patients are best suited to a short-course neuroactive steroid rather than—or in addition to—traditional antidepressants and psychotherapy.

What changed this week is the treatment architecture. For the first time, the United States has an oral medicine specifically approved for postpartum depression that is taken for only 14 days. The clinical evidence suggests symptom improvement can begin within days; the next test will be how safely and effectively that promise translates into routine maternal mental-health care.